JP2019507166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507166A5 JP2019507166A5 JP2018545874A JP2018545874A JP2019507166A5 JP 2019507166 A5 JP2019507166 A5 JP 2019507166A5 JP 2018545874 A JP2018545874 A JP 2018545874A JP 2018545874 A JP2018545874 A JP 2018545874A JP 2019507166 A5 JP2019507166 A5 JP 2019507166A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- patient
- combination
- pharmaceutically acceptable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 16
- 229960005277 gemcitabine Drugs 0.000 claims description 16
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 229940127089 cytotoxic agent Drugs 0.000 claims description 14
- 239000002955 immunomodulating agent Substances 0.000 claims description 11
- 238000002619 cancer immunotherapy Methods 0.000 claims description 9
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 claims description 7
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 claims description 7
- 101150112743 HSPA5 gene Proteins 0.000 claims description 7
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 101150028578 grp78 gene Proteins 0.000 claims description 7
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 2
- 206010073069 Hepatic cancer Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 208000018501 Lymphatic disease Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims description 2
- 201000001531 bladder carcinoma Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 208000015322 bone marrow disease Diseases 0.000 claims description 2
- 210000000133 brain stem Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 2
- 229960001573 cabazitaxel Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 229960005167 everolimus Drugs 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 210000002510 keratinocyte Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000003849 large cell carcinoma Diseases 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000000088 lip Anatomy 0.000 claims description 2
- 201000002250 liver carcinoma Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 208000018555 lymphatic system disease Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- 229960002450 ofatumumab Drugs 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000010198 papillary carcinoma Diseases 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 208000000649 small cell carcinoma Diseases 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims description 2
- 210000002105 tongue Anatomy 0.000 claims description 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
- 229960003862 vemurafenib Drugs 0.000 claims description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021125151A JP7513574B2 (ja) | 2016-03-01 | 2021-07-30 | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 |
| JP2022204252A JP2023024618A (ja) | 2016-03-01 | 2022-12-21 | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301786P | 2016-03-01 | 2016-03-01 | |
| US62/301,786 | 2016-03-01 | ||
| PCT/US2017/020209 WO2017151775A1 (en) | 2016-03-01 | 2017-03-01 | Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021125151A Division JP7513574B2 (ja) | 2016-03-01 | 2021-07-30 | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507166A JP2019507166A (ja) | 2019-03-14 |
| JP2019507166A5 true JP2019507166A5 (https=) | 2020-04-09 |
| JP6997919B2 JP6997919B2 (ja) | 2022-01-18 |
Family
ID=59744351
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545874A Active JP6997919B2 (ja) | 2016-03-01 | 2017-03-01 | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 |
| JP2021125151A Active JP7513574B2 (ja) | 2016-03-01 | 2021-07-30 | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 |
| JP2022204252A Pending JP2023024618A (ja) | 2016-03-01 | 2022-12-21 | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021125151A Active JP7513574B2 (ja) | 2016-03-01 | 2021-07-30 | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 |
| JP2022204252A Pending JP2023024618A (ja) | 2016-03-01 | 2022-12-21 | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10821095B2 (https=) |
| EP (1) | EP3423055A4 (https=) |
| JP (3) | JP6997919B2 (https=) |
| KR (2) | KR102413412B1 (https=) |
| CN (1) | CN109195600A (https=) |
| AU (1) | AU2017227705A1 (https=) |
| IL (2) | IL299223A (https=) |
| WO (2) | WO2017151775A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017151775A1 (en) * | 2016-03-01 | 2017-09-08 | Intezyne Technologies | Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| US20230024119A1 (en) * | 2019-12-05 | 2023-01-26 | Bold Therapeutics, Inc. | Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers |
| US11730750B2 (en) | 2020-02-17 | 2023-08-22 | University Of Kentucky Research Foundation | Drugs for GRP78 cell surface translocation and Par-4 secretion |
| WO2021195763A1 (en) * | 2020-03-30 | 2021-10-07 | Bold Therapeutics Inc. | Antiviral ruthenate(iii) therapeutics |
| CN118450895A (zh) * | 2021-10-28 | 2024-08-06 | 博德疗法公司 | 反式-[四氯双(1h-吲唑)钌(iii)酸]钠改善蛋白酶体抑制剂抗性的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2152084B1 (en) * | 2007-06-11 | 2013-12-18 | Niiki Pharma Inc. | Method of manufacturing a ruthenium complex |
| CN103153303A (zh) | 2010-07-18 | 2013-06-12 | 尼基制药公司 | 使用钌络合物的联合疗法 |
| AU2011323832B2 (en) * | 2010-10-25 | 2016-06-02 | Niiki Pharma Inc. | Method of treating neuroendocrine tumors |
| US20170247455A1 (en) * | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| WO2017151775A1 (en) * | 2016-03-01 | 2017-09-08 | Intezyne Technologies | Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer |
-
2017
- 2017-03-01 WO PCT/US2017/020209 patent/WO2017151775A1/en not_active Ceased
- 2017-03-01 WO PCT/US2017/020190 patent/WO2017151762A1/en not_active Ceased
- 2017-03-01 KR KR1020187028391A patent/KR102413412B1/ko active Active
- 2017-03-01 CN CN201780027237.0A patent/CN109195600A/zh active Pending
- 2017-03-01 IL IL299223A patent/IL299223A/en unknown
- 2017-03-01 AU AU2017227705A patent/AU2017227705A1/en not_active Abandoned
- 2017-03-01 US US16/081,554 patent/US10821095B2/en active Active
- 2017-03-01 EP EP17760721.5A patent/EP3423055A4/en active Pending
- 2017-03-01 JP JP2018545874A patent/JP6997919B2/ja active Active
- 2017-03-01 KR KR1020227017618A patent/KR20220075450A/ko not_active Ceased
-
2018
- 2018-08-26 IL IL261384A patent/IL261384B2/en unknown
-
2020
- 2020-09-29 US US17/036,628 patent/US11633380B2/en active Active
-
2021
- 2021-07-30 JP JP2021125151A patent/JP7513574B2/ja active Active
-
2022
- 2022-12-21 JP JP2022204252A patent/JP2023024618A/ja active Pending
-
2023
- 2023-04-19 US US18/303,267 patent/US20240091196A1/en not_active Abandoned
-
2025
- 2025-03-25 US US19/089,600 patent/US20250387370A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507166A5 (https=) | ||
| EP2127652B1 (en) | Method for treating cancer using anticancer agent in combination | |
| JP2022088662A (ja) | ツカレゾールまたはそのアナログを含む組成物 | |
| US20180071302A1 (en) | Syk inhibitors | |
| EP2979700B1 (en) | Antitumor agent including low dose irinotecan hydrochloride hydrate | |
| JP7513574B2 (ja) | がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用 | |
| JP2020524694A5 (https=) | ||
| RU2020102237A (ru) | Связывающие il-1-бета антитела для применения в лечении рака | |
| KR102566461B1 (ko) | 조합 요법 | |
| JP2016530219A5 (https=) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2018525358A5 (https=) | ||
| JP2019038796A5 (https=) | ||
| Hamaguchi et al. | 305 POSTER DNA cross-linking and in vivo antitumour activity of the extended pyrrolo [2, 1-c][1, 4] benzodiazepine dimer SG2057 (DRG-16) | |
| ES2426098T3 (es) | Composiciones farmacéuticas y su uso en el tratamiento del cáncer | |
| Zhu et al. | RETRACTED: Synergistic Antitumor Activities of Docetaxel and Octreotide Associated with Apoptotic-Upregulation in Castration-Resistant Prostate Cancer | |
| Lv et al. | Regulatory role of the transforming growth factor-β signaling pathway in the drug resistance of gastrointestinal cancers | |
| JP2016536282A5 (https=) | ||
| JP2009545609A5 (https=) | ||
| Sun et al. | Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells | |
| JP2008533021A5 (https=) | ||
| JP6023902B1 (ja) | 高齢又は末期の癌患者を治療又は寛解するための医薬組成物 | |
| JP5694782B2 (ja) | 肺癌、腺癌及び他の病状のための治療方法及び組成物 | |
| Stewart et al. | Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors | |
| EP2979701A1 (en) | Antitumor agent including irinotecan hydrochloride hydrate |